Dr. Gregory Owens JR.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 37
Licensed in Washington since 2011, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
OR license MD206222 · WA license MD60221603 (first issued 2011; active) -
Pediatric Allergy/Immunology Physician
WA license MD60221603 (first issued 2011; active) -
Pediatrics Physician
OR license MD206222
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
- The Vancouver Clinic Inc Ps (590 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 37
- Services billed
- 192
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Professional service for multiple injections of allergen | 27 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Portland, OR | 52 |
| Fluticasone Propionate Other prescribers in Portland, OR | 31 |
| Ipratropium Bromide Other prescribers in Portland, OR | 23 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Portland, OR | 23 |
| Azelastine Hcl Other prescribers in Portland, OR | 18 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Portland, OR | 17 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Portland, OR | 16 |
| Prednisone Other prescribers in Portland, OR | 15 |
| Dupixent Syringe (dupilumab) Other prescribers in Portland, OR | 14 |
| Tezspire (tezepelumab-ekko) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $55,042 in research payments for these studies, mostly to the institutions running them.
- A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca UK Limited - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04959448 - A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the U…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.